BioCentury
ARTICLE | Clinical News

Opicinumab: Additional Phase II data

September 26, 2016 7:00 AM UTC

Additional data from the double-blind, international Phase II SYNERGY trial in 412 evaluable patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS (...